156 related articles for article (PubMed ID: 35804954)
1. External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.
Janssens E; Schillebeeckx E; Zwijsen K; Raskin J; Van Cleemput J; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804954
[TBL] [Abstract][Full Text] [Related]
2. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Di Gilio A; Catino A; Lombardi A; Palmisani J; Facchini L; Mongelli T; Varesano N; Bellotti R; Galetta D; de Gennaro G; Tangaro S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429446
[TBL] [Abstract][Full Text] [Related]
3. Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
Lamote K; Vynck M; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29269578
[TBL] [Abstract][Full Text] [Related]
4. Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
Lamote K; Vynck M; Van Cleemput J; Thas O; Nackaerts K; van Meerbeeck JP
J Breath Res; 2016 Sep; 10(4):046001. PubMed ID: 27669062
[TBL] [Abstract][Full Text] [Related]
5. Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
Lamote K; Brinkman P; Vandermeersch L; Vynck M; Sterk PJ; Van Langenhove H; Thas O; Van Cleemput J; Nackaerts K; van Meerbeeck JP
Oncotarget; 2017 Oct; 8(53):91593-91602. PubMed ID: 29207669
[TBL] [Abstract][Full Text] [Related]
6. Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
Töreyin ZN; Ghosh M; Göksel Ö; Göksel T; Godderis L
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32050546
[TBL] [Abstract][Full Text] [Related]
7. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results.
Zwijsen K; Schillebeeckx E; Janssens E; Cleemput JV; Richart T; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
J Breath Res; 2023 Sep; 17(4):. PubMed ID: 37683624
[TBL] [Abstract][Full Text] [Related]
8. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
9. Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
Catino A; de Gennaro G; Di Gilio A; Facchini L; Galetta D; Palmisani J; Porcelli F; Varesano N
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207975
[TBL] [Abstract][Full Text] [Related]
10. Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research.
Janssens E; Mol Z; Vandermeersch L; Lagniau S; Vermaelen KY; van Meerbeeck JP; Walgraeve C; Marcq E; Lamote K
Front Oncol; 2022; 12():851785. PubMed ID: 35600344
[TBL] [Abstract][Full Text] [Related]
11. Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Brusselmans L; Arnouts L; Millevert C; Vandersnickt J; van Meerbeeck JP; Lamote K
Transl Lung Cancer Res; 2018 Oct; 7(5):520-536. PubMed ID: 30450290
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
13. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
15. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
16. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
[TBL] [Abstract][Full Text] [Related]
17. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for malignant pleural mesothelioma: current status.
Greillier L; Baas P; Welch JJ; Hasan B; Passioukov A
Mol Diagn Ther; 2008; 12(6):375-90. PubMed ID: 19035624
[TBL] [Abstract][Full Text] [Related]
20. Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics.
Gunatilake S; Lodge D; Neville D; Jones T; Fogg C; Bassett P; Begum S; Kerley S; Marshall L; Glaysher S; Elliott S; Stores R; Bishop L; Chauhan A
BMJ Open Respir Res; 2021 Jan; 8(1):. PubMed ID: 33414260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
